DCP-001
Phase 1Biologic
DCP-001 is one of 64 biologic programs targeting Ovarian Cancer. It is currently in Phase 1.
2
Indications
3
Total Trials
1
Active Trials
63
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Femara
NovartisPhase 3
Tecentriq
RochePhase 3
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 3
Tylenol
KKenvue Brands
Phase 3
Taxane
Bristol-Myers SquibbPhase 3
Rina-S
GenmabPhase 3
Carboplatin/paclitaxel
AstraZenecaPhase 3
Apatinib Mesylate
BBukwang Pharmaceutical
Phase 3
Salvage Chemotherapy
Daiichi SankyoPhase 3
Karenitecin
BBioNumerik Pharmaceuticals, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Myeloid Leukaemia1 trial
Acute Myeloid Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DCP-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]